Advertisement
Amendment Free access | 10.1172/JCI152477
Find articles by Hegde, M. in: JCI | PubMed | Google Scholar
Find articles by Mukherjee, M. in: JCI | PubMed | Google Scholar
Find articles by Grada, Z. in: JCI | PubMed | Google Scholar
Find articles by Pignata, A. in: JCI | PubMed | Google Scholar
Find articles by Landi, D. in: JCI | PubMed | Google Scholar
Find articles by Navai, S. in: JCI | PubMed | Google Scholar
Find articles by Wakefield, A. in: JCI | PubMed | Google Scholar
Find articles by Fousek, K. in: JCI | PubMed | Google Scholar
Find articles by Bielamowicz, K. in: JCI | PubMed | Google Scholar
Find articles by Chow, K. in: JCI | PubMed | Google Scholar
Find articles by Brawley, V. in: JCI | PubMed | Google Scholar
Find articles by Byrd, T. in: JCI | PubMed | Google Scholar
Find articles by Krebs, S. in: JCI | PubMed | Google Scholar
Find articles by Gottschalk, S. in: JCI | PubMed | Google Scholar
Find articles by Wels, W. in: JCI | PubMed | Google Scholar
Find articles by Baker, M. in: JCI | PubMed | Google Scholar
Find articles by Dotti, G. in: JCI | PubMed | Google Scholar
Find articles by Mamonkin, M. in: JCI | PubMed | Google Scholar
Find articles by Brenner, M. in: JCI | PubMed | Google Scholar
Find articles by Orange, J. in: JCI | PubMed | Google Scholar
Find articles by Ahmed, N. in: JCI | PubMed | Google Scholar
Published July 1, 2021 - More info
In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells that are redirected to single tumor antigens. Given the heterogeneous expression of antigens on glioblastomas, we hypothesized that a bispecific CAR molecule would mitigate antigen escape and improve the antitumor activity of T cells. Here, we created a CAR that joins a HER2-binding scFv and an IL13Rα2-binding IL-13 mutein to make a tandem CAR exodomain (TanCAR) and a CD28.ζ endodomain. We determined that patient TanCAR T cells showed distinct binding to HER2 or IL13Rα2 and had the capability to lyse autologous glioblastoma. TanCAR T cells exhibited activation dynamics that were comparable to those of single CAR T cells upon encounter of HER2 or IL13Rα2. We observed that TanCARs engaged HER2 and IL13Rα2 simultaneously by inducing HER2-IL13Rα2 heterodimers, which promoted superadditive T cell activation when both antigens were encountered concurrently. TanCAR T cell activity was more sustained but not more exhaustible than that of T cells that coexpressed a HER2 CAR and an IL13Rα2 CAR, T cells with a unispecific CAR, or a pooled product. In a murine glioblastoma model, TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival. Thus, TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.
Meenakshi Hegde, Malini Mukherjee, Zakaria Grada, Antonella Pignata, Daniel Landi, Shoba A. Navai, Amanda Wakefield, Kristen Fousek, Kevin Bielamowicz, Kevin K.H. Chow, Vita S. Brawley, Tiara T. Byrd, Simone Krebs, Stephen Gottschalk, Winfried S. Wels, Matthew L. Baker, Gianpietro Dotti, Maksim Mamonkin, Malcolm K. Brenner, Jordan S. Orange, Nabil Ahmed
Original citation: J Clin Invest. 2016;126(8):3036–3052. https://doi.org/10.1172/JCI83416
Citation for this amendment: J Clin Invest. 2021;131(13):e152477. https://doi.org/10.1172/JCI152477
The Editors posted an Expression of Concern for this article following notification that two images in Figure 9D were subsequently published as distinct samples in another paper (1). An institutional review of the primary data supports that the images in the JCI article are correct and that no corrective action is required.
See the related article at Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.